MAP kinases and the inflammatory signaling cascade as targets for the treatment of endometriosis?

Expert Opinion on Therapeutic Targets

Volumn 19, Issue 11, 2015, Pages 1465-1483

  Santulli, Pietro ^a   Marcellin, Louis ^a   Tosti, Claudia ^b   Chouzenoux, Sandrine ^a   Cerles, Olivier ^a   Borghese, Bruno ^a   Batteux, Frédéric ^a,c   Chapron, Charles ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b UNIVERSITY OF SIENA   (Italy)

^c Institut Cochin   (France)

Author keywords

endometriosis; infertility; inflammation; mitogen activated protein kinases; non hormonal treatments; pain

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PROSTAGLANDIN; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; PROTEIN KINASE INHIBITOR;

ANGIOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CHRONIC INFLAMMATION; DISEASE CONTROL; DRUG POTENCY; ENDOMETRIOSIS; HUMAN; IMMUNE SYSTEM; IN VITRO STUDY; NONHUMAN; OVULATION; OXIDATIVE STRESS; PAIN; PAIN INTENSITY; PERITONEAL FLUID; PERITONEUM MACROPHAGE; PHAGOCYTOSIS; POSITIVE FEEDBACK; PROTEIN ANALYSIS; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; STEROIDOGENESIS; ANIMAL; DRUG DESIGN; DRUG EFFECTS; FEMALE; INFLAMMATION; METABOLISM; PATHOPHYSIOLOGY;

ANIMALS; DRUG DESIGN; ENDOMETRIOSIS; FEMALE; HUMANS; INFLAMMATION; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION;

EID: 84947017924     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2015.1090974     Document Type: Review

References (191)

1. de Ziegler D, Borghese B, Chapron C. Endometriosis and infertility: pathophysiology and management. Lancet 2010;376:730-8
2. Giudice LC, Kao LC. Endometriosis. Lancet 2004;364:1789-99
3. Berkley KJ, Rapkin AJ, Papka RE. The pains of endometriosis. Science 2005;308:1587-9
4. Sampson JA. Peritoneal endometriosis due to menstrual dissemination of endometrial tissue into the peritoneal cavity. Am J Obstet Gynecol 1927;14:442-69
5. Chapron C, Bourret A, Chopin N, et al. Surgery for bladder endometriosis: longterm results and concomitant management of associated posterior deep lesions. Hum Reprod 2010;25:884-9
6. Chapron C, Chopin N, Borghese B, et al. Deeply infiltrating endometriosis: pathogenetic implications of the anatomical distribution. Hum Reprod 2006;21:1839-45
7. Santulli P, Marcellin L, Noel JC, et al. Sphingosine pathway deregulation in endometriotic tissues. Fertil Steril 2012;97:904-11
8. Santulli P, Borghese B, Noel JC, et al. Hormonal Therapy Deregulates Prostaglandin-Endoperoxidase Synthase 2 (PTGS2) Expression in Endometriotic Tissues. J Clin Endocrinol Metab 2014;99:881-90
9. Zhao Y, Gong P, Chen Y, et al. Dual suppression of estrogenic and inflammatory activities for targeting of endometriosis. Sci Transl Med 2015;7:271ra279
10. Streuli I, de Ziegler D, Borghese B, et al. New treatment strategies and emerging drugs in endometriosis. Expert Opin Emerg Drugs 2012
11. Streuli I, de Ziegler D, Santulli P, et al. An update on the pharmacological management of endometriosis. Expert Opin Pharmacother 2013;14:291-305
12. Simoens S, Dunselman G, Dirksen C, et al. The burden of endometriosis: costs and quality of life of women with endometriosis and treated in referral centres. Hum Reprod 2012;27:1292-9
13. Leconte M, Chapron C, Dousset B. Surgical treatment of rectal endometriosis. J Chir (Paris) 2007;5-10
14. Bulun SE. Endometriosis. N Engl J Med 2009;360:268-79
15. Hsu CY, Hsieh TH, Tsai CF, et al. miRNA-199a-5p regulates VEGFA in endometrial mesenchymal stem cells and contributes to the pathogenesis of endometriosis. J Pathol 2014;232:330-43
16. Laschke MW, Giebels C, Menger MD. Vasculogenesis: A new piece of the endometriosis puzzle. Hum Reprod Update 2011;17:628-36
17. Laschke MW, Menger MD. In vitro and in vivo approaches to study angiogenesis in the pathophysiology and therapy of endometriosis. Hum Reprod Update 2007;13:331-42
18. Laschke MW, Menger MD. Anti-angiogenic treatment strategies for the therapy of endometriosis. Hum Reprod Update 2012;18:682-702
19. Anaf V, Simon P, El Nakadi I, et al. Relationship between endometriotic foci and nerves in rectovaginal endometriotic nodules. Hum Reprod 2000;15:1744-50
20. Yuge A, Nasu K, Matsumoto H, et al. Collagen gel contractility is enhanced in human endometriotic stromal cells: A possible mechanism underlying the pathogenesis of endometriosis-associated fibrosis. Hum Reprod 2007;22:938-44
21. Itoga T, Matsumoto T, Takeuchi H, et al. Fibrosis and smooth muscle metaplasia in rectovaginal endometriosis. Pathol Int 2003;53:371-5
22. Jackson LW, Schisterman EF, Dey-Rao R, et al. Oxidative stress and endometriosis. Hum Reprod 2005;20:2014-20
23. Carvalho LF, Samadder AN, Agarwal A, et al. Oxidative stress biomarkers in patients with endometriosis: systematic review. Arch Gynecol Obstet 2012;286:1033-40
24. Rana N, Braun DP, House R, et al. Basal and stimulated secretion of cytokines by peritoneal macrophages in women with endometriosis. Fertil Steril 1996;65:925-30
25. Kats R, Collette T, Metz CN, et al. Marked elevation of macrophage migration inhibitory factor in the peritoneal fluid of women with endometriosis. Fertil Steril 2002;78:69-76
26. Eisermann J, Gast MJ, Pineda J, et al. Tumor necrosis factor in peritoneal fluid of women undergoing laparoscopic surgery. Fertil Steril 1988;50:573-9
27. Harada T, Yoshioka H, Yoshida S, et al. Increased interleukin-6 levels in peritoneal fluid of infertile patients with active endometriosis. Am J Obstet Gynecol 1997;176:593-7
28. Akoum A, Lemay A, McColl S, et al. Elevated concentration and biologic activity of monocyte chemotactic protein-1 in the peritoneal fluid of patients with endometriosis. Fertil Steril 1996;66:17-23
29. Lambert S, Santulli P, Chouzenoux S, et al. Endometriosis: increasing concentrations of serum interleukin-1beta and interleukin-1sRII is associated with the deep form of this pathology. J Gynecol Obstet Biol Reprod (Paris) 2014;43:735-43
30. Santulli P, Borghese B, Chouzenoux S, et al. Interleukin-19 and interleukin-22 serum levels are decreased in patients with ovarian endometrioma. Fertil Steril 2013;99:219-26
31. Santulli P, Borghese B, Chouzenoux S, et al. Serum and peritoneal interleukin-33 levels are elevated in deeply infiltrating endometriosis. Hum Reprod 2012;27:2001-9
32. Wu MH, Sun HS, Lin CC, et al. Distinct mechanisms regulate cyclooxygenase-1 and-2 in peritoneal macrophages of women with and without endometriosis. Mol Hum Reprod 2002;8:1103-10
33. Chen DB, Yang ZM, Hilsenrath R, et al. Stimulation of prostaglandin (PG) F2 alpha and PGE2 release by tumour necrosis factor-alpha and interleukin-1 alpha in cultured human luteal phase endometrial cells. Hum Reprod 1995;10:2773-80
34. Attar E, Tokunaga H, Imir G, et al. Prostaglandin E2 via steroidogenic factor-1 coordinately regulates transcription of steroidogenic genes necessary for estrogen synthesis in endometriosis. J Clin Endocrinol Metab 2009;94:623-31
35. Bulun SE, Yang S, Fang Z, et al. Role of aromatase in endometrial disease. J Steroid Biochem Mol Biol 2001;79:19-25
36. Noyes RW, Hertig AT, Rock J. Dating the endometrial biopsy. Am J Obstet Gynecol 1975;122:262-3
37. Salamonsen LA, Zhang J, Brasted M. Leukocyte networks and human endometrial remodelling. J Reprod Immunol 2002;57:95-108
38. Challis JR, Lockwood CJ, Myatt L, et al. Inflammation and pregnancy. Reprod Sci 2009;16:206-15
39. Weiss G, Goldsmith LT, Taylor RN, et al. Inflammation in reproductive disorders. Reprod Sci 2009;16:216-29
40. Ferreira SH, Vane JR. Prostaglandins: their disappearance from and release into the circulation. Nature 1967;216:868-73
41. Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and-2. J Biol Chem 1996;271:33157-60
42. Langenbach R, Morham SG, Tiano HF, et al. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 1995;83:483-92
43. Breyer RM, Bagdassarian CK, Myers SA, et al. Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol 2001;41:661-90
44. Wu MH, Wang CA, Lin CC, et al. Distinct regulation of cyclooxygenase-2 by interleukin-1beta in normal and endometriotic stromal cells. J Clin Endocrinol Metab 2005;90:286-95
45. Chishima F, Hayakawa S, Sugita K, et al. Increased expression of cyclooxygenase-2 in local lesions of endometriosis patients. Am J Reprod Immunol 2002;48:50-6
46. Ota H, Igarashi S, Sasaki M, et al. Distribution of cyclooxygenase-2 in eutopic and ectopic endometrium in endometriosis and adenomyosis. Hum Reprod 2001;16:561-6
47. Tamura M, Sebastian S, Yang S, et al. Interleukin-1beta elevates cyclooxygenase-2 protein level and enzyme activity via increasing its mRNA stability in human endometrial stromal cells: an effect mediated by extracellularly regulated kinases 1 and 2. J Clin Endocrinol Metab 2002;87:3263-73
48. Tamura M, Sebastian S, Yang S, et al. Up-regulation of cyclooxygenase-2 expression and prostaglandin synthesis in endometrial stromal cells by malignant endometrial epithelial cells. A paracrine effect mediated by prostaglandin E2 and nuclear factor-kappa B. J Biol Chem 2002;277:26208-16
49. Bulun SE, Fang Z, Imir G, et al. Aromatase and endometriosis. Semin Reprod Med 2004;22:45-50
50. Bulun SE, Monsavais D, Pavone ME, et al. Role of estrogen receptor-beta in endometriosis. Semin Reprod Med 2012;30:39-45
51. Noble LS, Simpson ER, Johns A, et al. Aromatase expression in endometriosis. J Clin Endocrinol Metab 1996;81:174-9
52. Tsai SJ, Wu MH, Lin CC, et al. Regulation of steroidogenic acute regulatory protein expression and progesterone production in endometriotic stromal cells. J Clin Endocrinol Metab 2001;86:5765-73
53. Stocco DM, Clark BJ. Regulation of the acute production of steroids in steroidogenic cells. Endocr Rev 1996;17:221-44
54. Noble LS, Takayama K, Zeitoun KM, et al. Prostaglandin E2 stimulates aromatase expression in endometriosisderived stromal cells. J Clin Endocrinol Metab 1997;82:600-6
55. Sun HS, Hsiao KY, Hsu CC, et al. Transactivation of steroidogenic acute regulatory protein in human endometriotic stromalcells is mediated by the prostaglandin EP2 receptor. Endocrinology 2003;144:3934-42
56. Hsu CC, Lu CW, Huang BM, et al. Cyclic adenosine 3',5'-monophosphate response element-binding protein and CCAAT/enhancer-binding protein mediate prostaglandin E2-induced steroidogenic acute regulatory protein expression in endometriotic stromal cells. Am J Pathol 2008;173:433-41
57. Zeitoun KM, Bulun SE. Aromatase: A key molecule in the pathophysiology of endometriosis and a therapeutic target. Fertil Steril 1999;72:961-9
58. Yang S, Fang Z, Suzuki T, et al. Regulation of aromatase P450 expression in endometriotic and endometrial stromal cells by CCAAT/enhancer binding proteins (C/EBPs): decreased C/EBPbeta in endometriosis is associated with overexpression of aromatase. J Clin Endocrinol Metab 2002;87:2336-45
59. Noel JC, Anaf V, Borghese B, et al. The steroidogenic factor-1 protein is not expressed in various forms of endometriosis but is strongly present in ovarian cortical or medullary mesenchymatous cells adjacent to endometriotic foci. Fertil Steril 2011;95:2655-7
60. Yang HJ, Shozu M, Murakami K, et al. Spatially heterogeneous expression of aromatase P450 through promoter II is closely correlated with the level of steroidogenic factor-1 transcript in endometrioma tissues. J Clin Endocrinol Metab 2002;87:3745-53
61. Haining RE, Cameron IT, van Papendorp C, et al. Epidermal growth factor in human endometrium: proliferative effects in culture and immunocytochemical localization in normal and endometriotic tissues. Hum Reprod 1991;6:1200-5
62. Croze F, Kennedy TG, Schroedter IC, et al. Expression of insulin-like growth factor-I and insulin-like growth factorbinding protein-1 in the rat uterus during decidualization. Endocrinology 1990;127:1995-2000
63. Pierro E, Minici F, Alesiani O, et al. Stromal-epithelial interactions modulate estrogen responsiveness in normal human endometrium. Biol Reprod 2001;64:831-8
64. Cooke PS, Buchanan DL, Lubahn DB, et al. Mechanism of estrogen action: lessons from the estrogen receptor-alpha knockout mouse. Biol Reprod 1998;59:470-5
65. Khan KN, Kitajima M, Hiraki K, et al. Immunopathogenesis of pelvic endometriosis: role of hepatocyte growth factor, macrophages and ovarian steroids. Am J Reprod Immunol 2008;60:383-404
66. Tsai SJ, Wu MH, Chen HM, et al. Fibroblast growth factor-9 is an endometrial stromal growth factor. Endocrinology 2002;143:2715-21
67. Wing LY, Chuang PC, Wu MH, et al. Expression and mitogenic effect of fibroblast growth factor-9 in human endometriotic implant is regulated by aberrant production of estrogen. J Clin Endocrinol Metab 2003;88:5547-54
68. Wing LY, Chen HM, Chuang PC, et al. The mammalian target of rapamycin-p70 ribosomal S6 kinase but not phosphatidylinositol 3-kinase-Akt signaling is responsible for fibroblast growth factor-9-induced cell proliferation. J Biol Chem 2005;280:19937-47
69. Leconte M, Nicco C, Ngo C, et al. The mTOR/AKT inhibitor temsirolimus prevents deep infiltrating endometriosis in mice. Am J Pathol 2011;179:880-9
70. Ngo C, Nicco C, Leconte M, et al. Protein kinase inhibitors can control the progression of endometriosis in vitro and in vivo. J Pathol 2010;222:148-57
71. Dmowski WP, Gebel HM, Braun DP. The role of cell-mediated immunity in pathogenesis of endometriosis. Acta Obstet Gynecol Scand Suppl 1994;159:7-14
72. Haney AF, Muscato JJ, Weinberg JB. Peritoneal fluid cell populations in infertility patients. Fertil Steril 1981;35:696-8
73. Dunselman GA, Hendrix MG, Bouckaert PX, et al. Functional aspects of peritoneal macrophages in endometriosis of women. J Reprod Fertil 1988;82:707-10
74. Bacci M, Capobianco A, Monno A, et al. Macrophages are alternatively activated in patients with endometriosis and required for growth and vascularization of lesions in a mouse model of disease. Am J Pathol 2009;175:547-56
75. Berbic M, Schulke L, Markham R, et al. Macrophage expression in endometrium of women with and without endometriosis. Hum Reprod 2009;24:325-32
76. Capobianco A, Rovere-Querini P. Endometriosis, a disease of the macrophage. Front Immunol 2013;4:9
77. Itoh F, Komohara Y, Takaishi K, et al. Possible involvement of signal transducer and activator of transcription-3 in cellcell interactions of peritoneal macrophages and endometrial stromal cells in human endometriosis. Fertil Steril 2013;99:1705-13
78. Osteen KG, Yeaman GR, Bruner-Tran KL. Matrix metalloproteinases and endometriosis. Semin Reprod Med 2003;21:155-64
79. Febbraio M, Hajjar DP, Silverstein RL. CD36: A class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J Clin Invest 2001;108:785-91
80. Linton MF, Fazio S. Class A scavenger receptors, macrophages, and atherosclerosis. Curr Opin Lipidol 2001;12:489-95
81. Wu MH, Shoji Y, Wu MC, et al. Suppression of matrix metalloproteinase-9 by prostaglandin E(2) in peritoneal macrophage is associated with severity of endometriosis. Am J Pathol 2005;167:1061-9
82. Chuang PC, Wu MH, Shoji Y, et al. Downregulation of CD36 results in reduced phagocytic ability of peritoneal macrophages of women with endometriosis. J Pathol 2009;219:232-41
83. Raiter-Tenenbaum A, Baranao RI, Etchepareborda JJ, et al. Functional and phenotypic alterations in peritoneal macrophages from patients with early and advanced endometriosis. Arch Gynecol Obstet 1998;261:147-57
84. Mathur S, Peress MR, Williamson HO, et al. Autoimmunity to endometrium and ovary in endometriosis. Clin Exp Immunol 1982;50:259-66
85. Isaacson KB, Coutifaris C, Garcia CR, et al. Production and secretion of complement component 3 by endometriotic tissue. J Clin Endocrinol Metab 1989;69:1003-9
86. Lousse JC, Defrere S, Van Langendonckt A, et al. Iron storage is significantly increased in peritoneal macrophages of endometriosis patients and correlates with iron overload in peritoneal fluid. Fertil Steril 2009;91:1668-75
87. Khan KN, Kitajima M, Hiraki K, et al. Escherichia coli contamination of menstrual blood and effect of bacterial endotoxin on endometriosis. Fertil Steril 2010;94:2860-3
88. Taylor RN, Lebovic DI, Mueller MD. Angiogenic factors in endometriosis. Ann N Y Acad Sci 2002;955:89-100
89. Groothuis PG, Nap AW, Winterhager E, et al. Vascular development in endometriosis. Angiogenesis 2005;8:147-56
90. Jones MK, Wang H, Peskar BM, et al. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 1999;5:1418-23
91. Tsujii M, Kawano S, Tsuji S, et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705-16
92. Williams CS, Tsujii M, Reese J, et al. Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 2000;105:1589-94
93. Ozawa Y, Murakami T, Tamura M, et al. A selective cyclooxygenase-2 inhibitor suppresses the growth of endometriosis xenografts via antiangiogenic activity in severe combined immunodeficiency mice. Fertil Steril 2006;86:1146-51
94. Laschke MW, Elitzsch A, Scheuer C, et al. Selective cyclo-oxygenase-2 inhibition induces regression of autologous endometrial grafts by down-regulation of vascular endothelial growth factor-mediated angiogenesis and stimulation of caspase-3-dependent apoptosis. Fertil Steril 2007;87:163-71
95. Gao Z, Zhang H, Liu J, et al. Cyclooxygenase-2-dependent oxidative stress mediates palmitate-induced impairment of endothelium-dependent relaxations in mouse arteries. Biochem Pharmacol 2014;91:474-82
96. Ma JQ, Ding J, Zhang L, et al. Ursolic acid protects mouse liver against CCl4-induced oxidative stress and inflammation by the MAPK/NF-kappaB pathway. Environ Toxicol Pharmacol 2014;37:975-83
97. Simoes MR, Aguado A, Fiorim J, et al. MAPK pathway activation by chronic lead-exposure increases vascular reactivity through oxidative stress/cyclooxygenase-2-dependent pathways. Toxicol Appl Pharmacol 2015;283:127-38
98. Agarwal A, Gupta S, Sharma RK. Role of oxidative stress in female reproduction. Reprod Biol Endocrinol 2005;3:28
99. Slater TF. Free-radical mechanisms in tissue injury. Biochem J 1984;222:1-15
100. Lemarechal H, Anract P, Beaudeux JL, et al. Impairment of thioredoxin reductase activity by oxidative stress in human rheumatoid synoviocytes. Free Radic Res 2007;41:688-98
101. Tsukahara H. Biomarkers for oxidative stress: clinical application in pediatric medicine. Curr Med Chem 2007;14:339-51
102. Schisterman EF, Faraggi D, Browne R, et al. TBARS and cardiovascular disease in a population-based sample. J Cardiovasc Risk 2001;8:219-25
103. Brewer J, Liu R, Lu Y, et al. Endothelin-1, oxidative stress, and endogenous angiotensin II: mechanisms of angiotensin II type I receptor autoantibody-enhanced renal and blood pressure response during pregnancy. Hypertension 2013;62:886-92
104. Huang QT, Zhang M, Zhong M, et al. Advanced glycation end products as an upstream molecule triggers ROS-induced sFlt-1 production in extravillous trophoblasts: A novel bridge between oxidative stress and preeclampsia. Placenta 2013;34:1177-82
105. Kavian N, Marut W, Servettaz A, et al. Reactive oxygen species-mediated killing of activated fibroblasts by arsenic trioxide ameliorates fibrosis in a murine model of systemic sclerosis. Arthritis Rheum 2012;64:3430-40
106. Ngo C, Chereau C, Nicco C, et al. Reactive oxygen species controls endometriosis progression. Am J Pathol 2009;175:225-34
107. Bolton JL. Quinoids, quinoid radicals, and phenoxyl radicals formed from estrogens and antiestrogens. Toxicology 2002;177:55-65
108. Okoh V, Deoraj A, Roy D. Estrogen-induced reactive oxygen speciesmediated signalings contribute to breast cancer. Biochim Biophys Acta 2011;1815:115-33
109. Santulli P, Chouzenoux S, Fiorese M, et al. Protein oxidative stress markers in peritoneal fluids of women with deep infiltrating endometriosis are increased. Hum Reprod 2015;30:49-60
110. Osborn BH, Haney AF, Misukonis MA, et al. Inducible nitric oxide synthase expression by peritoneal macrophages in endometriosis-associated infertility. Fertil Steril 2002;77:46-51
111. Lebovic DI, Chao VA, Taylor RN. Peritoneal macrophages induce RANTES (regulated on activation, normal T cell expressed and secreted) chemokine gene transcription in endometrial stromal cells. J Clin Endocrinol Metab 2004;89:1397-401
112. Wu MY, Ho HN, Chen SU, et al. Increase in the production of interleukin-6, interleukin-10, and interleukin-12 by lipopolysaccharide-stimulated peritoneal macrophages from women with endometriosis. Am J Reprod Immunol 1999;41:106-11
113. Egan SE, Weinberg RA. The pathway to signal achievement. Nature 1993;365:781-3
114. Campbell JS, Seger R, Graves JD, et al. The MAP kinase cascade. Recent Prog Horm Res 1995;50:131-59
115. Takashima A, Faller DV. Targeting the RAS oncogene. Expert Opin Ther Targets 2013;17:507-31
116. Dhanasekaran N, Premkumar Reddy E. Signaling by dual specificity kinases. Oncogene 1998;17:1447-55
117. De Luca A, Maiello MR, D'Alessio A, et al. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets 2012;16(Suppl 2):S17-27
118. Burotto M, Chiou VL, Lee JM, et al. The MAPK pathway across different malignancies: A new perspective. Cancer 2014;120:3446-56
119. Broom OJ, Widjaya B, Troelsen J, et al. Mitogen activated protein kinases: A role in inflammatory bowel disease? Clin Exp Immunol 2009;158:272-80
120. Kaminska B. MAPK signalling pathways as molecular targets for antiinflammatory therapy-from molecular mechanisms to therapeutic benefits. Biochim Biophys Acta 2005;1754:253-62
121. Chang F, McCubrey JA. P21(Cip1) induced by Raf is associated with increased Cdk4 activity in hematopoietic cells. Oncogene 2001;20:4354-64
122. Chang F, Steelman LS, McCubrey JA. Raf-induced cell cycle progression in human TF-1 hematopoietic cells. Cell Cycle 2002;1:220-6
123. Hoyle PE, Moye PW, Steelman LS, et al. Differential abilities of the Raf family of protein kinases to abrogate cytokine dependency and prevent apoptosis in murine hematopoietic cells by a MEK1-dependent mechanism. Leukemia 2000;14:642-56
124. Zha J, Harada H, Yang E, et al. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 1996;87:619-28
125. Weston CR, Balmanno K, Chalmers C, et al. Activation of ERK1/2 by deltaRaf-1:ER∗ represses Bim expression independently of the JNK or PI3K pathways. Oncogene 2003;22:1281-93
126. Ley R, Balmanno K, Hadfield K, et al. Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein. Bim. J Biol Chem 2003;278:18811-16
127. Harada H, Quearry B, Ruiz-Vela A, et al. Survival factor-induced extracellular signal-regulated kinase phosphorylates BIM, inhibiting its association with BAX and proapoptotic activity. Proc Natl Acad Sci U S A 2004;101:15313-17
128. Luciano F, Jacquel A, Colosetti P, et al. Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. Oncogene 2003;22:6785-93
129. Cardone MH, Roy N, Stennicke HR, et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998;282:1318-21
130. Garnett MJ, Marais R. Guilty as charged: B-RAF is a human oncogene. Cancer Cell 2004;6:313-19
131. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54
132. Libra M, Malaponte G, Bevelacqua V, et al. Absence of BRAF gene mutation in non-melanoma skin tumors. Cell Cycle 2006;5:968-70
133. Fransen K, Klintenas M, Osterstrom A, et al. Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis 2004;25:527-33
134. McCarthy SA, Samuels ML, Pritchard CA, et al. Rapid induction of heparin-binding epidermal growth factor/diphtheria toxin receptor expression by Raf and Ras oncogenes. Genes Dev 1995;9:1953-64
135. McCubrey JA, Steelman LS, Hoyle PE, et al. Differential abilities of activated Raf oncoproteins to abrogate cytokine dependency, prevent apoptosis and induce autocrine growth factor synthesis in human hematopoietic cells. Leukemia 1998;12:1903-29
136. Shelton JG, Moye PW, Steelman LS, et al. Differential effects of kinase cascade inhibitors on neoplastic and cytokinemediated cell proliferation. Leukemia 2003;17:1765-82
137. Ford PW, Hamden KE, Whitman AG, et al. Vascular endothelial growth factor augments human herpesvirus-8 (HHV-8/KSHV) infection. Cancer Biol Ther 2004;3:876-81
138. Hamden KE, Ford PW, Whitman AG, et al. Raf-induced vascular endothelial growth factor augments Kaposi's sarcoma-associated herpesvirus infection. J Virol 2004;78:13381-90
139. Hamden KE, Whitman AG, Ford PW, et al. Raf and VEGF: emerging therapeutic targets in Kaposi's sarcomaassociated herpesvirus infection and angiogenesis in hematopoietic and nonhematopoietic tumors. Leukemia 2005;19:18-26
140. Alexia C, Fallot G, Lasfer M, et al. An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against druginduced apoptosis. Biochem Pharmacol 2004;68:1003-15
141. Griffith CE, Zhang W, Wange RL. ZAP-70-dependent and-independent activation of Erk in Jurkat T cells. Differences in signaling induced by H2o2 and Cd3 cross-linking. J Biol Chem 1998;273:10771-6
142. Jimenez LA, Zanella C, Fung H, et al. Role of extracellular signal-regulated protein kinases in apoptosis by asbestos and H2O2. Am J Physiol 1997;273:L1029-35
143. Xiao L, Pimentel DR, Wang J, et al. Role of reactive oxygen species and NAD (P)H oxidase in alpha(1)-adrenoceptor signaling in adult rat cardiac myocytes. Am J Physiol Cell Physiol 2002;282:C926-34
144. Conde de la Rosa L, Schoemaker MH, Vrenken TE, et al. Superoxide anions and hydrogen peroxide induce hepatocyte death by different mechanisms: involvement of JNK and ERK MAP kinases. J Hepatol 2006;44:918-29
145. Knebel A, Rahmsdorf HJ, Ullrich A, et al. Dephosphorylation of receptor tyrosine kinases as target of regulation by radiation, oxidants or alkylating agents. EMBO J 1996;15:5314-25
146. Lander HM, Milbank AJ, Tauras JM, et al. Redox regulation of cell signalling. Nature 1996;381:380-1
147. Lee K, Esselman WJ. Inhibition of PTPs by H(2)O(2) regulates the activation of distinct MAPK pathways. Free Radic Biol Med 2002;33:1121-32
148. Lee WC, Choi CH, Cha SH, et al. Role of ERK in hydrogen peroxide-induced cell death of human glioma cells. Neurochem Res 2005;30:263-70
149. Lee JS, Kim SY, Kwon CH, et al. EGFR-dependent ERK activation triggers hydrogen peroxide-induced apoptosis in OK renal epithelial cells. Arch Toxicol 2006;80:337-46
150. Morotti M, Vincent K, Brawn J, et al. Peripheral changes in endometriosisassociated pain. Hum Reprod Update 2014;20:717-36
151. Anaf V, Chapron C, El Nakadi I, et al. Pain, mast cells, and nerves in peritoneal, ovarian, and deep infiltrating endometriosis. Fertil Steril 2006;86:1336-43
152. Anaf V, El Nakadi I, Simon P, et al. Preferential infiltration of large bowel endometriosis along the nerves of the colon. Hum Reprod 2004;19:996-1002
153. Anaf V, Simon P, El Nakadi I, et al. Hyperalgesia, nerve infiltration and nerve growth factor expression in deep adenomyotic nodules, peritoneal and ovarian endometriosis. Hum Reprod 2002;17:1895-900
154. McKinnon BD, Bertschi D, Bersinger NA, et al. Inflammation and nerve fiber interaction in endometriotic pain. Trends Endocrinol Metab 2015;26:1-10
155. Coosemans A, Moerman P, Vergote I, et al. Wilms' tumor gene 1 (WT1) overexpression in neurons in deep endometriosis: A pilot study. Fertil Steril 2009;91:1441-4
156. Ji RR, Suter MR. p38 MAPK, microglial signaling, and neuropathic pain. Mol Pain 2007;3:33
157. Ji RR, Gereau RWt, Malcangio M, et al. MAP kinase and pain. Brain Res Rev 2009;60:135-48
158. Ji RR, Woolf CJ. Neuronal plasticity and signal transduction in nociceptive neurons: implications for the initiation and maintenance of pathological pain. Neurobiol Dis 2001;8:1-10
159. Brawn J, Morotti M, Zondervan KT, et al. Central changes associated with chronic pelvic pain and endometriosis. Hum Reprod Update 2014;20:737-47
160. Raman M, Cobb MH. MAP kinase modules: many roads home. Curr Biol 2003;13:R886-8
161. Shaul YD, Seger R. The MEK/ERK cascade: from signaling specificity to diverse functions. Biochim Biophys Acta 2007;1773:1213-26
162. Chang F, Lee JT, Navolanic PM, et al. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: A target for cancer chemotherapy. Leukemia 2003;17:590-603
163. Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 2002;14:381-95
164. Kim TH, Yu Y, Luo L, et al. Activated AKT pathway promotes establishment of endometriosis. Endocrinology 2014;155:1921-30
165. Matsuzaki S, Darcha C. Co-operation between the AKT and ERK signaling pathways may support growth of deep endometriosis in a fibrotic microenvironment in vitrodagger. Hum Reprod 2015;30:1606-16
166. Leconte M, Nicco C, Ngo C, et al. Antiproliferative effects of cannabinoid agonists on deep infiltrating endometriosis. Am J Pathol 2010;177:2963-70
167. Yoshino O, Osuga Y, Hirota Y, et al. Possible pathophysiological roles of mitogen-activated protein kinases (MAPKs) in endometriosis. Am J Reprod Immunol 2004;52:306-11
168. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 2004;4:937-47
169. Huang F, Cao J, Liu Q, et al. MAPK/ERK signal pathway involved expression of COX-2 and VEGF by IL-1beta induced in human endometriosis stromal cells in vitro. Int J Clin Exp Pathol 2013;6:2129-36
170. Yamauchi N, Harada T, Taniguchi F, et al. Tumor necrosis factor-alpha induced the release of interleukin-6 from endometriotic stromal cells by the nuclear factor-kappaB and mitogenactivated protein kinase pathways. Fertil Steril 2004;82(Suppl 3):1023-8
171. Kim KH, Park JK, Choi YW, et al. Hexane extract of aged black garlic reduces cell proliferation and attenuates the expression of ICAM-1 and VCAM1 in TNF-alpha-activated human endometrial stromal cells. Int J Mol Med 2013;32:67-78
172. Guo Y, Chen Y, Liu LB, et al. IL-22 in the endometriotic milieu promotes the proliferation of endometrial stromal cells via stimulating the secretion of CCL2 and IL-8. Int J Clin Exp Pathol 2013;6:2011-20
173. Lee DH, Kim SC, Joo JK, et al. Effects of 17beta-estradiol on the release of monocyte chemotactic protein-1 and MAPK activity in monocytes stimulated with peritoneal fluid from endometriosis patients. J Obstet Gynaecol Res 2012;38:516-25
174. Carli C, Metz CN, Al-Abed Y, et al. Up-regulation of cyclooxygenase-2 expression and prostaglandin E2 production in human endometriotic cells by macrophage migration inhibitory factor: involvement of novel kinase signaling pathways. Endocrinology 2009;150:3128-37
175. Veillat V, Carli C, Metz CN, et al. Macrophage migration inhibitory factor elicits an angiogenic phenotype in human ectopic endometrial cells and triggers the production of major angiogenic factors via CD44, CD74, and MAPK signaling pathways. J Clin Endocrinol Metab 2010;95:E403-12
176. Chang KK, Liu LB, Jin LP, et al. NME1 suppression of endometrial stromal cells promotes angiogenesis in the endometriotic milieu via stimulating the secretion of IL-8 and VEGF. Int J Clin Exp Pathol 2013;6:2030-8
177. Zhou WD, Yang HM, Wang Q, et al. SB203580, a p38 mitogen-activated protein kinase inhibitor, suppresses the development of endometriosis by downregulating proinflammatory cytokines and proteolytic factors in a mouse model. Hum Reprod 2010;25:3110-16
178. Li MQ, Shao J, Meng YH, et al. NME1 suppression promotes growth, adhesion and implantation of endometrial stromal cells via Akt and MAPK/Erk1/2 signal pathways in the endometriotic milieu. Hum Reprod 2013;28:2822-31
179. Velarde MC, Aghajanova L, Nezhat CR, et al. Increased mitogen-activated protein kinase kinase/extracellularly regulated kinase activity in human endometrial stromal fibroblasts of women with endometriosis reduces 3',5'-cyclic adenosine 5'-monophosphate inhibition of cyclin D1. Endocrinology 2009;150:4701-12
180. Yotova IY, Quan P, Leditznig N, et al. Abnormal activation of Ras/Raf/MAPK and RhoA/ROCKII signalling pathways in eutopic endometrial stromal cells of patients with endometriosis. Hum Reprod 2011;26:885-97
181. Mori T, Ito F, Matsushima H, et al. G protein-coupled estrogen receptor 1 agonist G-1 induces cell cycle arrest in the mitotic phase, leading to apoptosis in endometriosis. Fertil Steril 2015
182. Cheng W, Chen L, Yang S, et al. Puerarin suppresses proliferation of endometriotic stromal cells partly via the MAPK signaling pathway induced by 17ss-estradiol-BSA. PLoS One 2012;7:e45529
183. Oh HK, Choi YS, Yang YI, et al. Leptin receptor is induced in endometriosis and leptin stimulates the growth of endometriotic epithelial cells through the JAK2/STAT3 and ERK pathways. Mol Hum Reprod 2013;19:160-8
184. Eaton JL, Unno K, Caraveo M, et al. Increased AKT or MEK1/2 activity influences progesterone receptor levels and localization in endometriosis. J Clin Endocrinol Metab 2013;98:E1871-9
185. Santulli P, Marcellin L, Chouzenoux S, et al. Proteine kinase inhibitor Vemurafenib controls the progression of endometriosis in vitro and in vivo. 12th World Congress on Endometriosis 2014
186. Leconte M, Santulli P, Chouzenoux S, et al. MAPK and VEGFR inhibition by Sorafenib controls the progression of endometriosis Reprod Sci 2015
187. Novella-Maestre E, Herraiz S, Vila-Vives JM, et al. Effect of antiangiogenic treatment on peritoneal endometriosis-associated nerve fibers. Fertil Steril 2012;98:1209-17
188. Siddappa D, Beaulieu E, Gevry N, et al. Effect of the transient pharmacological inhibition of Mapk3/1 pathway on ovulation in mice. PLoS ONE 2015;10:e0119387
189. Krajewska J, Handkiewicz-Junak D, Jarzab B. Sorafenib for the treatment of thyroid cancer: an updated review. Expert Opin Pharmacother 2015;16:573-83
190. Grunewald S, Jank A. New systemic agents in dermatology with respect to fertility, pregnancy, and lactation. J Dtsch Dermatol Ges 2015;13:277-89; quiz 290
191. Maleka A, Enblad G, Sjors G, et al. Treatment of metastatic malignant melanoma with vemurafenib during pregnancy. J Clin Oncol 2013;31:e192-3